{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:59Z","timestamp":1786991219203,"version":"build-2736575974"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jaad.2024.10.104","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T11:02:08Z","timestamp":1732446128000},"page":"724-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis"],"prefix":"10.1016","volume":"92","author":[{"given":"Xiaoyong","family":"Man","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Zaharieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u017cyna","family":"Pulka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"\u017bebrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhua","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lally","family":"Mekokishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2024.10.104_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1021537","article-title":"Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Kang","year":"2022","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.jaad.2024.10.104_bib2","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.3390\/jcm11164778","article-title":"Efficacy and safety of dimethyl fumarate in patients with moderate-to-severe plaque psoriasis: DIMESKIN-2, a multicentre single-arm Phase IIIB study","volume":"11","author":"Pellacani","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.104_bib3","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2024.10.104_bib4","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2024.10.104_bib5","article-title":"Efficacy and safety\u00a0of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.104_bib6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jamadermatol.2021.3616","article-title":"Out-of-pocket costs of specialty medications for psoriasis and psoriatic arthritis treatment in the medicare population","volume":"157","author":"Pourali","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2024.10.104_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.104_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00063030-200923010-00006","article-title":"Ustekinumab","volume":"23","author":"Weber","year":"2009","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.104_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40259-022-00563-5","article-title":"Comparison of pharmacokinetic similarity, immunogenicity, and safety of ustekinumab and BAT2206 in healthy Chinese male subjects in a double-blind, randomized, single-dose, parallel-group phase I trial","volume":"37","author":"Wu","year":"2023","journal-title":"BioDrugs"},{"issue":"9625","key":"10.1016\/j.jaad.2024.10.104_bib10","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.jaad.2024.10.104_bib11","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.104_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","article-title":"Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase III study","volume":"38","author":"Papp","year":"2024","journal-title":"BioDrugs"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224032663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224032663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:11:34Z","timestamp":1742343094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224032663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0190962224032663"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.10.104","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.10.104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}